The Phase 3 clinical trial NCT06604624, investigating semaglutide for the treatment of obesity, completed its primary phase on August 27, 2025. This multicenter study aimed to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection in obese non-diabetic adults.
Background
The clinical trial NCT06604624, titled "Semaglutide in Treatment of Obesity," is designed to evaluate treatments for weight management in adults with obesity. This study specifically compares the efficacy and safety of semaglutide injection with another intervention, HD1916, in non-diabetic adults.
Trial design
The Phase 3 clinical trial NCT06604624 is a multicenter, randomized, open, positive parallel controlled study. It enrolled 462 participants, focusing on adults with obesity who are non-diabetic. The trial's design involves comparing the efficacy and safety of once-weekly HD1916 and semaglutide injection, while also evaluating immunogenicity.
What this means
The primary completion of the Phase 3 trial NCT06604624 marks a significant milestone in the evaluation of semaglutide and HD1916 for obesity treatment. While specific efficacy and safety results are not yet available, the completion of this phase indicates that the main data collection period for the primary endpoints has concluded. The findings from this trial will be crucial for understanding the comparative profile of these interventions in managing obesity in non-diabetic adults, potentially informing future clinical practice and treatment guidelines once results are published.
Source
Information regarding the primary completion of trial NCT06604624 was retrieved from ClinicalTrials.gov, a public database of clinical studies. The event, "Phase 3 primary completion: NCT06604624," was recorded with an event date of 2025-08-27 on clinicaltrials.gov.